Esperion Therapeutics Inc (ESPR) Receives $78.04 Average PT from Analysts

Shares of Esperion Therapeutics Inc (NASDAQ:ESPR) have earned a consensus rating of “Buy” from the sixteen research firms that are currently covering the company, Marketbeat.com reports. Two equities research analysts have rated the stock with a sell recommendation, three have given a hold recommendation, nine have assigned a buy recommendation and two have given a strong buy recommendation to the company. The average 1-year price target among brokers that have issued a report on the stock in the last year is $78.04.

ESPR has been the subject of a number of recent research reports. Cowen set a $82.00 target price on Esperion Therapeutics and gave the company a “buy” rating in a research note on Friday, October 26th. ValuEngine upgraded Esperion Therapeutics from a “buy” rating to a “strong-buy” rating in a report on Thursday, November 1st. BidaskClub downgraded Esperion Therapeutics from a “buy” rating to a “hold” rating in a report on Friday, October 26th. Zacks Investment Research upgraded Esperion Therapeutics from a “hold” rating to a “buy” rating and set a $48.00 price target on the stock in a report on Tuesday, July 31st. Finally, Stifel Nicolaus initiated coverage on Esperion Therapeutics in a report on Friday, September 14th. They set a “buy” rating and a $89.00 price target on the stock.

In other Esperion Therapeutics news, major shareholder Boxer Capital, Llc sold 100,000 shares of the company’s stock in a transaction that occurred on Monday, November 5th. The stock was sold at an average price of $56.38, for a total transaction of $5,638,000.00. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, Director Roger S. Newton sold 9,400 shares of the company’s stock in a transaction that occurred on Tuesday, October 16th. The stock was sold at an average price of $50.01, for a total value of $470,094.00. Following the transaction, the director now owns 589,326 shares in the company, valued at approximately $29,472,193.26. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 152,327 shares of company stock worth $8,463,042. 14.50% of the stock is owned by company insiders.

Several hedge funds have recently bought and sold shares of ESPR. Opera Trading Capital purchased a new position in shares of Esperion Therapeutics during the 3rd quarter worth approximately $173,000. Pacer Advisors Inc. purchased a new position in shares of Esperion Therapeutics during the 3rd quarter worth approximately $226,000. Keybank National Association OH grew its holdings in shares of Esperion Therapeutics by 97.7% during the 2nd quarter. Keybank National Association OH now owns 7,663 shares of the biopharmaceutical company’s stock worth $300,000 after acquiring an additional 3,787 shares during the period. Metropolitan Life Insurance Co. NY grew its holdings in shares of Esperion Therapeutics by 40.6% during the 2nd quarter. Metropolitan Life Insurance Co. NY now owns 7,698 shares of the biopharmaceutical company’s stock worth $302,000 after acquiring an additional 2,224 shares during the period. Finally, Canada Pension Plan Investment Board purchased a new position in shares of Esperion Therapeutics during the 2nd quarter worth approximately $333,000.

NASDAQ ESPR opened at $50.17 on Friday. Esperion Therapeutics has a 1-year low of $33.06 and a 1-year high of $82.68. The stock has a market capitalization of $1.35 billion, a PE ratio of -7.19 and a beta of 2.20.

Esperion Therapeutics (NASDAQ:ESPR) last released its earnings results on Thursday, November 1st. The biopharmaceutical company reported ($1.86) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.64) by ($0.22). During the same quarter in the prior year, the company earned ($1.86) earnings per share. On average, analysts expect that Esperion Therapeutics will post -6.54 earnings per share for the current year.

Esperion Therapeutics Company Profile

Esperion Therapeutics, Inc, a lipid management company, focuses on developing and commercializing oral therapies for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C). Its lead product candidate is bempedoic acid/ezetimibe combination pill, a non-statin, orally available, LDL-C lowering therapy for patients with hypercholesterolemia and with atherosclerotic cardiovascular disease, and/or heterozygous familial hypercholesterolemia that is in Phase III long-term safety and tolerability study.

Featured Story: Dow Jones Industrial Average (DJIA)

Analyst Recommendations for Esperion Therapeutics (NASDAQ:ESPR)

Receive News & Ratings for Esperion Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Esperion Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply